Ivabradine: Cardiovascular effects

Recent Patents on Cardiovascular Drug Discovery

Volumn 4, Issue 1, 2009, Pages 61-66

  Rognoni, Andrea ^a   Bertolazzi, Marzia ^a   Macció, Sergio ^a   Rognoni, Giorgio ^a  

^a SANT'ANDREA HOSPITAL   (Italy)

Author keywords

Benzocyclobutane; Bradycardia; Coronary disease; Heart rate; Ivabradine

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; IVABRADINE; METOPROLOL; NITRATE; PLACEBO; PROPRANOLOL; BENZAZEPINE DERIVATIVE;

ANGINA PECTORIS; ANTIHYPERTENSIVE ACTIVITY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG BINDING; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STRUCTURE; ELECTROPHYSIOLOGY; ENDOTHELIAL DYSFUNCTION; EXERCISE TOLERANCE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART RATE VARIABILITY; HEMODYNAMICS; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; REVIEW; STABLE ANGINA PECTORIS; ANIMAL; CARDIOVASCULAR FUNCTION; DRUG EFFECT; HEART RATE;

ANIMALS; BENZAZEPINES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; CLINICAL TRIALS AS TOPIC; CORONARY CIRCULATION; CORONARY DISEASE; HEART RATE; HUMANS; MYOCARDIAL ISCHEMIA;

EID: 65549128780     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489009787260016     Document Type: Review

References (46)

1. Kannel WB, Kannel C, Paffenbarger RS Jr., Cupples LA. Heart rate and cardiovascular mortality: The Framingham Study. Am Heart J 1987; 113: 1489-1494.
2. Benetos A, Rudnichi A, Thomas F, et al. Influence of heart rate on mortality in a French population: Role of age, gender, and blood pressure. Hypertension 1999; 33 (1): 44-52.
3. Tardif JC, Ford I, Tendera M, Safar M, Guize M. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529-2536.
4. Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Abedini S, Hansen JF. Increased heart rate and reduced heart rate variability are associated with subclinical inflammation in middle-age and elderly subjects with no apparent heart disease. Eur Heart J 2004; 25: 363-370.
5. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart-rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477-1482.
6. Beere PA, GlagovS, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984; 226: 180-182.
7. North of England Stable Angina Guideline Development Group. Summary version of evidence based guideline for the primary care management of angina. Br Med J 1996; 312: 827-832.
8. Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue and sexual dysfunction. JAMA 2002; 288: 351-357.
9. Fogari R, Zoppi A, Corradi L, et al. Sexual function in hypertensive males treated with lisinopril and atenolol: A crossover study. Am J Hypertens 1998; 11: 1244-1247.
10. Andrikopoulos G, Dasopoulou C, Sakelliarou D, et al. Ivabradine: A selective If Inhibitor in the treatment of stable angina. Recent Patent Cardiovasc Drug Discov 2006; 1: 277-282.
11. Henderson RA, Pocock SJ, Clayton TC, et al. Second randomized intervention treatment of angina (RITA - 2) trial participants. 7-Year outcome in the RITA-2 trial: Coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003; 42: 1161-1170.
12. Camm AJ, Lau CP. Electrophysiological effects of a single intravenous administration of ivabradine (S16257) in adult patients with normal baseline electrophysiology. Drugs R D 2003; 4: 83-89.
13. f current inhibition with ivabradine. Drugs 2004; 64: 1757-1765.
14. Di Francesco D. The pacemaker current If plays an important role in regulating SA node pacemaker activity. Cardiovasc Res 1995; 30(2): 307-308.
15. Brown HF, Di Francesco D, Noble SJ. How does adrenaline accelerate the heart? Nature 1979; 280(5719): 235-236.
16. Dobzynski H, Nikolsky VP, Sambelahvilli AT, et al. Site of origin and molecular substrate of atrioventricular junctional rhythm in the rabbit heart. Circ Res 2003; 93(11): 1102-1110.
17. Barbuti A, Baruscotti M, Di Francesco D. The pacemaker current: From basics to the clinics. J Cardiovasc Electrophysiol 2007; 18(3): 342-347.
18. Baruscotti M, Bucchi A, Di Francesco D. Physiology and pharmacology of the cardiac pacemaker ("funny") current. Pharmacol Ther 2005; 107(1): 59-79.
19. Shi W, Wymore R, Yu H, et al. Distribution and prevalence of hyperpolarization-activated cation channel (HCN) mRNA expression in cardiac tissues. Circ Res 1999; 85: e1-6.
20. Di Francesco D, Borer JS. The funny current: Cellular basis for the control of heart rate. Drugs 2007; 67(2): 15-24.
21. Di Francesco D, Tortora P. Direct activation of cardiac pacemaker channels by intracellular cyclic AMP. Nature 1991; 351(6322): 145-147.
22. Ishii T, Takano M, Xie LH, et al. Molecular characterization of the hyperpolarization-activated cation channel in a rabbit heart sinoatrial node. J Biol Chem 1999; 274: 12835-12839.
23. Vaccari T, Moroni A, Rocchi M, et al. The human gene coding coding for HCN 2, a pacemaker channel of the heart. Biochim Biophys Acta 1999; 1446: 419-425.
24. Di Francesco D. Pacemaker mechanism in cardiac tissue. Annu Rev Physiol 1993; 55: 455-472.
25. Benetos A, Rudnichi A, Thomas F, et al. Influence of heart rate on mortality in a French population: Role of age, gender, and blood pressure. Hypertension 1999; 33(1): 44-52.
26. Bucchi A, Tognati A, Milanesi R, et al. Properties of ivabradine-induced block of HCN 1 and HCN 4 pacemaker channels. J Physiol 2006; 572(2): 335-346.
27. Vilaine JP, Thollon C, Villeneuve N, et al. Procorolan, a new selective If current inhibitor. Eur Heart J 2003; 5: G26-G35.
28. Monnet X, Ghaleh B, Colin P, et al. Effect of heart reduction with ivabradine on exercise - induced myocardial ischaemia and stunning. J Pharmacol Exp Ther 2001; 299: 1133-1139.
29. Colin P, Ghaleh B, Monnet X, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Circ Physiol 2003; 284: H676-682.
30. Beardeaux A. Preclinical results with If current inhibition by ivabradine. Drugs 2007; 67(2): 25-33.
31. Monnet X, Colin P, Ghaleh B, et al. Heart rate reduction during exercise-induced myocardial ischaemia and stunning. Eur Heart J 2004; 25: 579-586.
32. Lei L, Zhou R, Zheng W, et al. Bradycardia induces angiogenesis, increases coronary reserve, and preserves function of the postinfarcted heart. Circulation 2004; 110: 796-802.
33. Mulder P, Thuillez C. In: Camm J, Tandera M, Eds. Heart rate slowing for myocardial dysfunction/heart failure: Rationale and preclinical studies. Heart rate slowing by If current inhibition. Adv Cardiol 2006; 43: 97-105.
34. Neusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: Benefit from selective bradycardic agents. Br J Pharmacol 2008; 153: 1589-1601.
35. Langenbach MR, Schmitz-Spanke S, Brockert M, et al. Comparison of a ..-blocker and an If current inhibitor in rabbits with myocardial infarction. J Cardiovasc Surg 2006; 47: 719-725.
36. Thorin E, Drouin A, Gendro M, et al. Chronic heart rate reduction by ivabradine prevents cerebrovascular dysfunction in dyslipidemic mice. Arch Mal Coeur Vaiss 2007; 100(II): 653.
37. Custodis F, Baumhakel M, Schlimmer N, et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apoliprotein E-deficient mice. Circulation 2008; 117: 2377-2387.
38. Borer JS, Fox K, Jaillon P, et al. Antianginal and antiiaschemic effect of ivabradine, an I (f) inhibitor in stable angina: A randomized, double-blind, mulcentered, placebo-controlled trial. Circulation 2003; 107: 817-823.
39. Tardif JC, Ford I, Tendera M, et al. For the INITIATIVE Investigators. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529-2536.
40. Ruzyllo W, Tendera M, Ford I, et al. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: A 3-month randomised, double-blind, multicentre, noninferioriry trial. Drugs 2007; 67: 393-405.
41. Lopez-Bscos L, Filpova S, Martos R. Long- term safety and antianginal efficacy of the If current inhibitor ivabradine in patients with chronic stable angina. A one-year randomized, double-blind, multicenter trial. Eur Heart J 2004; 25: 876.
42. Joannides R, Moore N, Iacob M, et al. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propanolol on systemic and cardiac hemodynamics at rest and during exercise. Br J Clin Pharmacol 2006; 61 (2): 127-137.
43. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. On behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular dysfunction (BEAUTIFUL): A randomized, double-blind, placebo-controlled trial. Lancet 2008; 372: 807-816.
44. Jondeau G, Korewicki J, Vasiliauskns D. Effect of ivabradine in patients with left ventricular systolic dysfunction and coronary artery disease (abstract 2637). Eur Heart J 2004; 25: 451.
45. Benatar, V., Lerebours-Pigeonniere, G., Tardif, J.-C., Thorin, E., Rheaume, E.: US20080200450A1 (2008).
46. Vasylyev, D., Lu, Q., Mark, B., Edward, K., Shan, Q.: WO2008121735A1 (2008).